Evidence map›Paper›PMID 41255710›Full record

ArticleNAR molecular medicine2025

IgAim: cell surface Ig-aimed immune memory erasers for the therapy of autoimmune diseases and B leukemia.

Hiroshi Arakawa

Abstract read
In one paragraph

Article in NAR molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hiroshi ArakawaIFOM ETS - The AIRC Institute of Molecular Oncology, 20139 Milan, Italy.ORCID https://orcid.org/0000-0002-8103-4549

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases are caused by the misdirection of the immune system as the side effect of antibody diversity, wherein each B cell possesses unique characteristics defined by its antibodies. To address this issue, I have developed several cell surface immunoglobulin (Ig)-aimed immune memory erasers (IgAim) that consist of toxins explicitly targeted to cell surface Ig (sIg) on B cells. IgAim is created by replacing the receptor binding domain of diphtheria toxin with Staphylococcal protein A (SpA), affibodies, or specific antigens. The toxins IgAimG and IgAimA selectively killed sIgG

Identifiers

PMID41255710
PMCPMC12429969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.